Malignant Pleural Mesothelioma Global Clinical Trials Review, H2, 2017

  • ID: 4459360
  • Clinical Trials
  • Region: Global
  • 178 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Aduro BioTech Inc
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • MORE
Malignant Pleural Mesothelioma Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Malignant Pleural Mesothelioma Global Clinical Trials Review, H2, 2017" provides an overview of Malignant Pleural Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Pleural Mesothelioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc. across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aduro BioTech Inc
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Malignant Pleural Mesothelioma Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Malignant Pleural Mesothelioma
Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
Sep 27, 2017: Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Disclaimer
Source

List of Tables
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2017*
Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2017*
Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Malignant Pleural Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Region (%), 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2017*
Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2017*
Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Malignant Pleural Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Eli Lilly and Co
  • Merck & Co Inc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Bayer AG
  • Sellas Life Sciences Group Ltd
  • MolMed SpA
  • Aduro BioTech Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll